Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm
Abstract
BACKGROUND
Few ex vivo continuous renal replacement therapy (CRRT) studies to determine transmembrane clearance (CLTM) have resulted in direct dosage recommendations for patients on CRRT. Comparing the results of these studies with pharmacokinetic assessments in critically ill patients on CRRT could validate their findings and help guide dosage selection.
METHODS
CLTM was combined with non-renal clearance and used for Monte Carlo simulations to derive an ex vivo dosing algorithm for cefepime, meropenem, levofloxacin and micafungin regimens at varying CRRT effluent rates (ERs). Criteria for optimal dose selection depended on overall exposure (AUC24 h) and drug-specific pharmacodynamic efficacy targets. Plasma collected from CRRT patients, as part of standard care, were analysed and concentrations fitted to pharmacokinetic models. Bayesian estimates were then used to re-simulate selected dosing regimens. Predictive performance of the ex vivo dosing algorithm was assessed by median prediction error (MPE) for AUC24 h at a given dose.
RESULTS
Ex vivo algorithms demonstrated good performance with MPEs within ±30% for cefepime and meropenem, while for levofloxacin, larger MPE (-22 to -52%) deviations were observed across different ER ranges. For cefepime, meropenem and levofloxacin, optimal attainment of their respective pharmacodynamic target was predicted with the ex vivo algorithm derived dosing regimens. Micafungin displayed no ex vivo CLTM, and standard dosing resulted in…
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.